We’d love to hear your feedback on this activity. It helps us to continually improve our products.
University of Nevada, Las Vegas, NV, USA
Jeffrey Cummings, MD ScD, is the Joy Chambers-Grundy professor of brain science, director of the Chambers-Grundy Center for Transformative Neuroscience, and co-director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), USA. read more
Prof. Cummings is globally recognized for his contributions to Alzheimer’s disease research, drug development and clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through many awards, including the Ronald and Nancy Reagan Research Award of the National Alzheimer’s Association (2008), the Distinguished Scientist Award from the American Association of Geriatric Psychiatry (2010), a Lifetime Achievement Award from the Society for Behavioral and Cognitive Neurology (2017), the Bengt Winblad Lifetime Achievement Award from the Alzheimer’s Association (2019), and the Alzheimer’s Drug Discovery Foundation’s Melvin R Goodes Prize.
Prof. Cummings was formerly director of the Mary S Easton Center for Alzheimer’s Disease Research at UCLA and director of the Cleveland Clinic Lou Ruvo Center for Brain Health. His interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. Prof. Cummings has authored or edited 43 books and published over 900 peer-reviewed papers.
Prof. Jeffrey Cummings discloses: Advisory board or panel fees from Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, ReMYND, Roche and Signant Health. Consulting fees from Acadia, Acumen, ALZpath, Artery, Biogen, Biohaven, Bristol Myers Squibb, Eisai, Eli Lilly, EQT Life Sciences (formerly LSP), Fosun, GAP Foundation, Janssen, Karuna, Kinoxis, Lighthouse, Lundbeck, Merck, MoCA Cognition, New Amsterdam Pharma, Novo Nordisk, Optoceutics, Otsuka, Oxford Brain Diagnostics, Praxis, Prothena, ReMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, Sinaptica, TrueBinding and Vaxxinity. Grants/research support from the National Institute of General Medical Sciences and the National Institute on Aging. Other financial or material support from Neuropsychiatric Inventory (NPI) copyright. Stock/shareholder (self-managed) from Acumen, Alzheon, Artery, Behrens, MedAvante-Prophase and Vaxxinity.
University of Toronto, ON, Canada
Krista L Lanctôt has a PhD in clinical pharmacology from the University of Toronto, and holds the Bernick chair in geriatric psychopharmacology. She is a senior scientist in geriatric psychiatry and in the Hurvitz Brain Sciences Program at Sunnybrook Research Institute, research co-director in the Department of Psychiatry at Sunnybrook Health Sciences Centre and the head of neuropsychopharmacology research. She is also a professor of psychiatry and of pharmacology/toxicology, and vice chair of basic and clinical sciences in the Department of Psychiatry at the University of Toronto, Toronto, ON, Canada. read more
Prof. Lanctôt is an active researcher with more than 400 published papers, and editor of the 2021 book “Apathy: Clinical and Neuroscientific Perspectives from Neurology and Psychiatry”. Her group’s research has focused on optimizing the treatment of cognition and neuropsychiatric symptoms associated with dementia and in predementia states. She has designed and executed clinical trials evaluating novel treatments of agitation in dementia.
Prof. Krista Lanctôt discloses: Advisory board or panel fees from Bright Minds, Exciva, Lundbeck, Novo Nordisk and Otsuka, and Boehringer Ingelheim (relationship terminated). Consulting fees from Bristol Myers Squibb, Cerevel Therapeutics, Exciva, Ironshore Pharma, Kondor Pharma (relationship terminated) and Praxis Therapeutics. Grants/research support from Cerevel Therapeutics. Speaker Bureau fees from Eisai Co., Ltd, Lundbeck and Novo Nordisk (all relationships terminated).
University of Miami, FL, USA
James E Galvin, MD, MPH, is professor of neurology and psychiatry & behavioural sciences, and the Alexandria and Bernard Schoninger endowed chair for memory disorders at the University of Miami Miller School of Medicine. read more
He is division chief for cognitive neurology, founding director of the Comprehensive Center for Brain Health, director and principal investigator of the Lewy Body Dementia Research Center of Excellence, and principal investigator for the Native Alzheimer’s Disease Resource Center in Minority Aging Research.
Dr Galvin has authored over 375 scientific publications (h-index=73). He is principal investigator on 12 active NIH grants and has received over $120 million in research funding from the National Institutes of Health, Disease Associations, Private and Family Foundations.
Prof. James Galvin discloses: Consulting fees from Biogen, Bristol Myers Squibb, Cognivue, Eisai, Eli Lilly, GE Healthcare, Lundbeck, Roche and Thema Medical.
Learn more about the prevalence, impact and management of agitation in Alzheimer’s dementia.
All touchIME CME activities are accredited. Learners can claim ACCME credits upon completion of the activities. This content is for healthcare professionals only.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Or use a .
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
